December 15, 2006Blood Coagulation & Fibrinolysis

Combination of r-tPA with the high-affinity Class I GPIIb/IIIa antagonist roxifiban synergistically enhanced clot lysis in vitro, whereas the Class II antagonist orbofiban did not.

Q: What is the clinical evidence from this study?

Study design: Other. Intervention: r-tPA and GPIIb/IIIa antagonists (roxifiban or orbofiban) vs. Class II antagonists (orbofiban). Primary outcome: clot lysis.

View Full Paper

Ask AI

Bookmark

Population

Human whole blood (in-vitro model)

Comparison

Combination of active form of roxifiban or… vs Comparison between Class I and Class II…

Design

Preclinical

Key result

Combination of r-tPA with the high-affinity Class I GPIIb/IIIa antagonist roxifiban synergistically enhanced clot lysis in vitro, whereas the Class II antagonist orbofiban did not.

Authors

SMShaker A. Mousa

Discussion

Member takes

Overview

High-affinity Class I GPIIb/IIIa antagonists may enhance r-tPA thrombolysis in vitro; leaves open in vivo efficacy and clinical translation.

Structured PICO

Population

Human whole blood (in-vitro model)

Intervention

Combination of active form of roxifiban (XV459; Class I GPIIb/IIIa antagonist) or active form of orbofiban (Class II) with a subeffective concentration of recombinant tissue plasminogen activator (r-tPA)

Comparator

Comparison between Class I and Class II antagonists, and r-tPA alone

Outcome

Dynamics of platelet/fibrin clot formation, strength, and lysis measured by thrombelastographysurrogate

High-affinity Class I GPIIb/IIIa antagonists, but not low-affinity Class II antagonists, synergistically enhance thrombolysis when combined with low levels of r-tPA in vitro.

Cite This Study

Shaker A. Mousa (2006) studied this question. r-tPA and GPIIb/IIIa antagonists (roxifiban or orbofiban) vs. Class II antagonists (orbofiban) was evaluated on clot lysis. Combination of r-tPA with the high-affinity Class I GPIIb/IIIa antagonist roxifiban synergistically enhanced clot lysis in vitro, whereas the Class II antagonist orbofiban did not.

synapsesocial.com/papers/6a93f71ca09a696dc39c454d https://doi.org/10.1097/mbc.0b013e3280116c36

View Full Paper

Ask AI

Bookmark

December 15, 2006Blood Coagulation & Fibrinolysis

Combination of r-tPA with the high-affinity Class I GPIIb/IIIa antagonist roxifiban synergistically enhanced clot lysis in vitro, whereas the Class II antagonist orbofiban did not.

View Full Paper

Ask AI

Bookmark

Population

Human whole blood (in-vitro model)

Comparison

Combination of active form of roxifiban or… vs Comparison between Class I and Class II…

Design

Preclinical

Key result

Combination of r-tPA with the high-affinity Class I GPIIb/IIIa antagonist roxifiban synergistically enhanced clot lysis in vitro, whereas the Class II antagonist orbofiban did not.

Authors

SMShaker A. Mousa

Discussion

Member takes

Overview

High-affinity Class I GPIIb/IIIa antagonists may enhance r-tPA thrombolysis in vitro; leaves open in vivo efficacy and clinical translation.

Structured PICO

Population

Human whole blood (in-vitro model)

Intervention

Comparator

Comparison between Class I and Class II antagonists, and r-tPA alone

Outcome

Dynamics of platelet/fibrin clot formation, strength, and lysis measured by thrombelastographysurrogate

High-affinity Class I GPIIb/IIIa antagonists, but not low-affinity Class II antagonists, synergistically enhance thrombolysis when combined with low levels of r-tPA in vitro.

Cite This Study

synapsesocial.com/papers/6a93f71ca09a696dc39c454d https://doi.org/10.1097/mbc.0b013e3280116c36

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark